Login / Signup

Combinatorial development of nebulized mRNA delivery formulations for the lungs.

Allen Yujie JiangJacob WittenIdris O RajiFeyisayo EwejeCorina MacIsaacSabrina MengFavour A OladimejiYizong HuRajith Singh MananRobert S LangerDaniel G Anderson
Published in: Nature nanotechnology (2023)
Inhaled delivery of mRNA has the potential to treat a wide variety of diseases. However, nebulized mRNA lipid nanoparticles (LNPs) face several unique challenges including stability during nebulization and penetration through both cellular and extracellular barriers. Here we develop a combinatorial approach addressing these barriers. First, we observe that LNP formulations can be stabilized to resist nebulization-induced aggregation by altering the nebulization buffer to increase the LNP charge during nebulization, and by the addition of a branched polymeric excipient. Next, we synthesize a combinatorial library of ionizable, degradable lipids using reductive amination, and evaluate their delivery potential using fully differentiated air-liquid interface cultured primary lung epithelial cells. The final combination of ionizable lipid, charge-stabilized formulation and stability-enhancing excipient yields a significant improvement in lung mRNA delivery over current state-of-the-art LNPs and polymeric nanoparticles.
Keyphrases
  • drug delivery
  • binding protein
  • fatty acid
  • cancer therapy
  • endothelial cells
  • cystic fibrosis
  • human health
  • high glucose
  • ionic liquid
  • oxidative stress
  • climate change
  • diabetic rats
  • walled carbon nanotubes